Co-Diagnostics To Present At Robins Equity Research Roundup 2017

Published: Sep 25, 2017

SALT LAKE CITY--(BUSINESS WIRE)--Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that it will be presenting at the Third Annual Robins Equity Research Roundup, held September 25 – 27, 2017 near Portland, Oregon.

Sponsored by Catalyst Research Management Group, RIA, the Equity Research Roundup offers an opportunity for individual investors and professional money managers to become acquainted with up-and-coming public and private companies. Presenters represent a range of industries, and the goals of the conference also include facilitating an environment for the management of these companies to introduce themselves to influential members of the investment community. Co-Diagnostics CEO Dwight Egan will be presenting at 7:30 am PDT on September 26th.

Mr. Egan remarked: “We are excited for the opportunity to kick off this year’s Equity Research Roundup. Marc Robins’ experience advocating for newly public and micro-cap companies provides an ideal environment for Co-Diagnostics to present our story to key players in the finance world, and we anticipate that it will resonate with those participants looking for a micro-cap investment prospect with our potential.”

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Disclaimer:

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Co-Diagnostics
Andrew Benson, Investor Relations
801-438-1036
investors@codiagnostics.com

Back to news